title: Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
abstract: Xanthine oxidase and its products, uric acid and ROS, have been implicated in the pathogenesis of cardiovascular disease, such as hypertension. We have previously reported that allopurinol inhibition of XO does not alter the progression of deoxycorticosterone acetate (DOCA)-salt hypertension in rats. However other researchers have observed a reduction in blood pressure after allopurinol treatment in the same model. To resolve this controversy, in this study we used the newer and more effective XO inhibitor febuxostat, and hypothesized that a more complete XO blockade might impair hypertension development and its end-organ consequences. We used DOCA-salt hypertensive rats and administered vehicle (salt water) or febuxostat (orally, 5 mg/kg/day in salt water) in a short-term "reversal" experiment (2 weeks of treatment 3 weeks after DOCA-salt beginning) and a long-term "prevention" experiment (treatment throughout 4 weeks of DOCA-salt). We confirmed XO inhibition by febuxostat by measuring circulating and tissue levels of XO metabolites. We found an overall increase in hypoxanthine (XO substrate) and decrease in uric acid (XO product) levels following febuxostat treatment. However, despite a trend for reduced blood pressure in the last week of long-term febuxostat treatment, no statistically significant difference in hemodynamic parameters was observed in either study. Additionally, no change was observed in relative heart and kidney weight. Aortic media/lumen ratio was minimally improved by long-term febuxostat treatment. Additionally, febuxostat incubation in vitro did not modify contraction of aorta or vena cava to norepinephrine, angiotensin II or endothelin-1. We conclude that XO inhibition is insufficient to attenuate hypertension in the rat DOCA-salt model, although beneficial vascular effects are possible.
authors: Department of Physiology, Georgia Health Sciences University, Augusta, Georgia, United States of America. iszasz@georgiahealth.edu
authors: Theodora
authors: T
authors: Szasz
authors: Robert Patrick
authors: RP
authors: Davis
authors: Hannah S
authors: HS
authors: Garver
authors: Robert J
authors: RJ
authors: Burnett
authors: Gregory D
authors: GD
authors: Fink
authors: Stephanie W
authors: SW
authors: Watts
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D003900:Desoxycorticosterone / Q000494:pharmacology*; D000069465:Febuxostat; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013844:Thiazoles / Q000494:pharmacology*; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors*
chemical_list: D013844:Thiazoles; D000069465:Febuxostat; D003900:Desoxycorticosterone; D014969:Xanthine Oxidase
references: Hypertens Res. 2006 Nov;29(11):915-21
references: 17345792
references: Nephron Physiol. 2008;108(4):p69-78
references: 18434753
references: Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):517-9
references: 17439425
references: J Physiol Pharmacol. 2006 Sep;57(3):343-57
references: 17033089
references: Hypertension. 2004 Feb;43(2):329-34
references: 14707156
references: JAMA. 2008 Aug 27;300(8):924-32
references: 18728266
references: Pharmacol Rev. 2006 Mar;58(1):87-114
references: 16507884
references: Am J Physiol Heart Circ Physiol. 2010 Dec;299(6):H1891-901
references: 20852048
references: Phys Sportsmed. 2011 Nov;39(4):98-123
references: 22293773
references: Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4754-9
references: 9539811
references: Hypertension. 2003 Jun;41(6):1183-90
references: 12707287
references: N Engl J Med. 2005 Dec 8;353(23):2450-61
references: 16339094
references: Hypertens Res. 2008 May;31(5):931-40
references: 18712049
references: Am J Physiol Renal Physiol. 2008 Apr;294(4):F710-8
references: 18216151
references: Nucleosides Nucleotides Nucleic Acids. 2008 Aug;27(8):967-78
references: 18696365
references: J Hypertens. 2004 Jul;22(7):1333-40
references: 15201549
references: Hypertension. 2005 May;45(5):934-9
references: 15837840
references: N Engl J Med. 2008 Oct 23;359(17):1811-21
references: 18946066
references: Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H281-8
references: 18487445
references: Histol Histopathol. 2008 Oct;23(10):1241-8
references: 18712676
references: Am J Hypertens. 2005 Jul;18(7):910-6
references: 16053986
references: Life Sci. 2005 Mar 4;76(16):1835-47
references: 15698861
references: Hypertension. 2001 Nov;38(5):1101-6
references: 11711505
references: Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61
references: 22052584
references: Drugs. 2008;68(13):1865-74
references: 18729537
references: J Cardiovasc Pharmacol. 2010 Dec;56(6):627-34
references: 20881613
references: Blood Press. 2005;14(2):120-5
references: 16036490
references: Nephrol Dial Transplant. 2008 Apr;23(4):1179-85
references: 18048425
references: Clin Sci (Lond). 2006 Feb;110(2):243-53
references: 16271043
references: Kidney Int. 2005 May;67(5):1739-42
references: 15840020
references: Curr Hypertens Rep. 2010 Apr;12(2):135-42
references: 20424957
references: Arthritis Rheum. 2008 Nov 15;59(11):1540-8
references: 18975369
references: J Biol Chem. 2003 Jan 17;278(3):1848-55
references: 12421831
references: Rheumatology (Oxford). 2010 Oct;49(10):1929-34
references: 20573693
references: BMC Geriatr. 2012 Mar 21;12:11
references: 22436129